| Nov 20 |
Caribou Biosciences to Participate in Upcoming Investor Conferences
|
| Nov 10 |
Caribou Biosciences, Inc. (NASDAQ:CRBU) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
|
| Nov 8 |
Caribou Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
| Nov 7 |
Caribou Bioscience GAAP EPS of -$0.38 beats by $0.06, revenue of $2.02M misses by $1.07M
|
| Nov 6 |
Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Lags Revenue Estimates
|
| Nov 6 |
Caribou Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
|
| Oct 31 |
Is Caribou Biosciences (CRBU) a Promising Gene Editing Stock?
|
| Sep 30 |
Caribou Biosciences: CB-010, chRDNA Technology Continue To Show Promise In Gene Editing
|
| Sep 25 |
Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024
|
| Sep 18 |
With 60% ownership, Caribou Biosciences, Inc. (NASDAQ:CRBU) boasts of strong institutional backing
|
